EVEREST-HN 1: EVolution of a patiEnt-REported Symptom-based Risk Stratification sySTem
EVolution of a patiEnt-REported Symptom-based Risk Stratification sySTem to Redesign the Suspected Head and Neck Cancer Referral Pathway (Phase 1)
1 other identifier
observational
165
1 country
4
Brief Summary
Can a patient-reported symptom-based risk stratification system improve the suspected head and neck cancer (HNC) pathway? Our methodology includes six interlinked work packages to deliver our aim, with EVEREST-HN 1 encompassing the first of these and seeking to optimise a patient-reported symptom inventory for HNC and outline requirement specification for the SYmptom iNput Clinical (SYNC) system.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2023
Shorter than P25 for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 17, 2023
CompletedFirst Submitted
Initial submission to the registry
May 9, 2023
CompletedFirst Posted
Study publicly available on registry
June 18, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2023
CompletedOctober 3, 2023
October 1, 2023
9 months
May 9, 2023
October 2, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Inventory and specification for the SYmptom iNput Clinical (SYNC) system
To optimise a patient-reported symptom inventory for HNC and outline requirement specification for the SYmptom iNput Clinical (SYNC) system
September 2022 - August 2023
Secondary Outcomes (1)
To further explore the current suspected HNC pathway and the language used when discussing symptoms.
September 2022 - August 2023
Study Arms (2)
Patients
Approximately 150 adults referred for suspected HNC will be recruited.
Staff
Approximately 15 ENT and Maxillofacial) clinicians will be recruited.
Interventions
Eligibility Criteria
Patients Recruitment will aim for variation in age, ethnicity, socio-economic status, presenting symptoms. Clinicians Clinical staff involved in HNC diagnosis. Varying in seniority (consultant, registrar) and specialty (ENT, maxillofacial)
You may qualify if:
- Patients:
- Adults ≥ 18 years referred via suspected HNC pathway without previous history of HNC
- Participants willing and able to give informed consent for participation in the study.
- Clinicians:
- Staff at participating sites involved in the diagnostic pathway for people with suspected HNC.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Royal Marsden NHS Foundation Trustlead
- University of Leedscollaborator
Study Sites (4)
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
Liverpool University Hospitals NHS Foundation Trust
Liverpool, United Kingdom
Luton & Dunstable University Hospital
Luton, United Kingdom
Oxford NHS Foundation Trust
Oxford, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Vinidh Paleri
Royal Marsden NHS Foundation Trust
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 9, 2023
First Posted
June 18, 2023
Study Start
March 17, 2023
Primary Completion
November 30, 2023
Study Completion
November 30, 2023
Last Updated
October 3, 2023
Record last verified: 2023-10
Data Sharing
- IPD Sharing
- Will not share